DUPIXENT 300 MG / 2 ML — DIN 02470365
DUPILUMAB : 300 MG / 2 ML · SANOFI-AVENTIS CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is DUPIXENT?
DUPIXENT 300 MG / 2 ML contains DUPILUMAB : 300 MG / 2 ML. It is listed in the Health Canada Drug Product Database under DIN 02470365, held by SANOFI-AVENTIS CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 06-Feb-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DUPIXENT used for?
Atopic Dermatitis (6mo+), Asthma (6yr+), COPD (Adults), CRSwNP (Adults), Eosinophilic Esophagitis (1yr+, 15kg+), Prurigo Nodularis (Adults), Chronic Spontaneous Urticaria (12yr+).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Dupilumab cost around the world?
Dupilumab is listed on 15 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 1 | 36 | AUD███.██ |
| Romania | max producer price | 2 | 11 | RON███.██ |
| Italy | prezzo al pubblico (classe A) | 8 | 10 | EUR███.██ |
| Luxembourg | reimbursement | 8 | 8 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 1 | 6 | CZK███.██ |
| Greece | producer price (ex-factory) | 6 | 6 | EUR███.██ |
| Norway | max AUP (pharmacy retail) | 1 | 6 | NOK███.██ |
| Austria | KVP (Kassenverkaufspreis) | 4 | 4 | EUR███.██ |
| Iceland | max wholesale | 1 | 4 | ISK███.██ |
| Saudi Arabia | public | 4 | 4 | SAR███.██ |
| Slovakia | categorised final price | 4 | 4 | EUR███.██ |
| United Arab Emirates | public | 2 | 3 | AED███.██ |
| Bahrain | retail (max) | 1 | 3 | BHD███.██ |
| Hungary | producer price (ex-factory) | 2 | 2 | HUF███.██ |
| South Africa | single exit price | 2 | 2 | ZAR███.██ |
109 pack listings across 47 brand entries and 13 price bases, refreshed 08 Sep 2026. Ranges span every Dupilumab pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Dupilumab in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Dupilumab — 5 DINs, of which 4 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANOFI-AVENTIS CANADA INC | 5 | 4 | DUPIXENT | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 300 MG / 2 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | Single-use pre-filled syringe with needle shield or pre-filled pen. Packs of 1 or 2. |
| Storage | Store at 2-8°C. (Note: Detailed storage section 11 not fully provided in snippet, but standard for biologics). |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Dupilumab |
|---|---|
| ATC code | D11AH05 |
| AHFS class | 90:24.16.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02470365 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2470365 |
| Brand name | DUPIXENT |
| Generic / active ingredient | DUPILUMAB : 300 MG / 2 ML |
| Market authorization holder | SANOFI-AVENTIS CANADA INC |
| Health Canada schedule | Schedule D |
| ATC code | D11AH05 |
| ATC anatomical main group | D — Dermatologicals |
| ATC therapeutic subgroup | D11AH |
| Current status | MARKETED |
| Status date | 06-Feb-2018 |
| Original market date | 2018-03-22 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Subcutaneous injection. Adults (Atopic Dermatitis/PN/CSU): Initial 600mg, then 300mg Q2W. Asthma: 200mg or 300mg Q2W. COPD/CRSwNP: 300mg Q2W. EoE: Weight-based dosing (up to 300mg QW).
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation or component of the container.
Warnings and precautions
Not for acute asthma/COPD symptoms. Do not stop corticosteroids abruptly. Hypersensitivity reactions (anaphylaxis, serum sickness) reported.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 5 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| DUPIXENT | 200 MG / 1.14 ML | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | 02492504 |
| DUPIXENT | 300 MG / 2 ML | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | 02510049 |
| DUPIXENT | 200 MG / 1.14 ML | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | 02524252 |
| DUPIXENT | 100 MG / 0.67 ML | SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED PRE MARKET | 02526190 |
2 · Same class — other molecules in ATC D11AH
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Dupilumab | DUPIXENT | 5 | 4 | Yes |
| Abrocitinib | CIBINQO | 3 | 3 | Yes |
| Alitretinoin | HANZEMA · PANRETIN · TOCTINO | 5 | 2 | Yes |
| Tacrolimus | LEO PHARMA - TACROLIMUS · PROTOPIC | 4 | 2 | Yes |
| Tralokinumab | ADTRALZA | 2 | 2 | Yes |
| Lebrikizumab | EBGLYSS | 2 | 2 | Yes |
| Pimecrolimus | ELIDEL | 1 | 1 | Yes |
| Ruxolitinib | OPZELURA | 1 | 1 | Yes |
| Delgocitinib | ANZUPGO | 1 | 1 | Yes |
| Crisaborole | EUCRISA | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC D11A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| D11AX | Brimonidine · Deoxycholic Acid · Eflornithine · Finasteride · Hydroquinone · +6 more | 466 | 88 |
| D11AF | Wart And Anti-Corn Preparations | 33 | 1 |
| D11AA | Antihidrotics | 397 | 0 |
| D11AC | Cetrimide · Medicated Shampoos · Others · Povidone-Iodine · Selenium Compounds · +1 more | 27 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DUPIXENT called?
Also recorded in Canada as: 2 ML dupilumab 150 MG/ML Prefilled Syringe [Dupixent] (US), 1.14 ML dupilumab 175 MG/ML Prefilled Syringe [Dupixent] (US), 2 ML dupilumab 150 MG/ML Auto-Injector [Dupixent] (US), 1.14 ML dupilumab 175 MG/ML Auto-Injector [Dupixent] (US), 0.67 ML dupilumab 150 MG/ML Prefilled Syringe [Dupixent] (US), 2 ML dupilumab 150 MG/ML Prefilled Syringe (US), 1.14 ML dupilumab 175 MG/ML Prefilled Syringe (US), 2 ML dupilumab 150 MG/ML Auto-Injector (US), 1.14 ML dupilumab 175 MG/ML Auto-Injector (US), 0.67 ML dupilumab 150 MG/ML Prefilled Syringe (US), DUPILUMAB (US).
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.